Home > Insider Trading > Filing (0000919574-20-003060)

Filing Details

Accession Number:: 0000919574-20-003060
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-04-29 20:22:33
Reporting Period:: 2020-04-27

Accepted Time:: 2020-04-29 20:22:33
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1385818	Aytu Bioscience Inc	AYTU	Pharmaceutical Preparations (2834)	470883144

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1601086	Armistice Capital, Llc	510 Madison Avenue, 7Th Floor New York NY 10022	Yes	No	No	No
1633584	Ltd. Fund Master Capital Armistice	C/O Dms Corporate Services Ltd. 20 Genesis Close, P.o. Box 314 Grand Cayman E9 KY1-1104	Yes	No	No	No
1706140	Steven Boyd	C/O Armistice Capital, Llc 510 Madison Avenue, 7Th Floor New York NY 10022	Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-04-27	5,000,000	$1.25	5,108,921	No	4	M	Direct
Common Stock	Acquisiton	2020-04-27	0	$0.00	5,108,921	No	4	M	Indirect	See Footnote 1
Common Stock	Disposition	2020-04-27	5,108,921	$1.82	0	No	4	S	Direct
Common Stock	Disposition	2020-04-27	0	$0.00	0	No	4	S	Indirect	See Footnote 1

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	M	Indirect	See Footnote 1
No	4	S	Direct
No	4	S	Indirect	See Footnote 1

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants	Disposition	2020-04-27	5,000,000	$0.00	5,000,000	$1.25
Common Stock	Warrants	Disposition	2020-04-27	0	$0.00	0	$1.25

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2025-01-10	No	4	M	Direct
0		2025-01-10	No	4	M	Indirect

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Warrants	$15.75	2022-03-21	85,151	85,151	Direct
Common Stock	Warrants	$15.75	2022-03-21	0	85,151	Indirect
Common Stock	Warrant	$10.80	2023-03-06	222,222	222,222	Direct
Common Stock	Warrant	$10.80	2023-03-06	0	222,222	Indirect
Common Stock	Warrant	$10.80	2023-03-23	100,000	100,000	Direct
Common Stock	Warrant	$10.80	2023-03-23	0	100,000	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2022-03-21	85,151	85,151	Direct
2022-03-21	0	85,151	Indirect
2023-03-06	222,222	222,222	Direct
2023-03-06	0	222,222	Indirect
2023-03-23	100,000	100,000	Direct
2023-03-23	0	100,000	Indirect

Footnotes

The reported shares of the issuer's common stock (the "Shares") are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands corporation (the "Master Fund"), and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC ("Armistice Capital"), a Delaware limited liability company, as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
This constitutes the weighted average sale price. The prices ranged from $1.70 to $2.09. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 40% beneficial owner of the Shares following such exercise.
These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the Shares following such exercise.
These are the same warrants reported as having been acquired by the Master Fund in the Form 4 filed by the Reporting Persons in respect of the issuer on February 10, 2020. The amount of Shares and other consideration that the Master Fund is entitled to receive upon its full exercise of the warrants was misstated in that filing and is corrected hereby. In particular, at the time of the merger between the Issuer and Innovus Pharmaceuticals, Inc. ("Innovus") that became effective on February 14, 2020 (the "Merger"), the Master Fund held certain warrants to acquire 76,191 shares of Innovus' common stock at an exercise price of $15.75 per share. Pursuant to the Merger, those warrants became exercisable for: (i) 85,151 Shares; and (ii) any remaining non-transferable contingent value rights held by the Master Fund, which represent the Master Fund's right to receive certain payments in the form of additional Shares and/or cash if specified revenue and profitability milestones are achieved.